Document resource
Background Randomised controlled trials have shown clinical benefits of extrafine formulation single-inhaler triple therapy (SITT) consisting of beclometasone/formoterol/glycopyrronium (BDP/FF/G) in asthma patients uncontrolled on a combination of an inhaled corticosteroid and long-acting beta-agonist with at least one exacerbation in the prior year, 1 yet there is limited evidence in a real-world setting.Methods TriMaximize is a prospective, non-interventional, multicentre study describing patient-characteristics and therapy pathways in adults with moderate-to-severe asthma, treated with BDP/FF/G.This data set describes the treatment impact with BDP/FF/G on moderate and severe exacerbation rates and rescue medication use from the UK cohort (NCT04902573).Results Of 166 patients enrolled across 20 UK centres, 147 are included (19 excluded as inclusion criteria not fulfilled or missing core baseline data) in the full analysis set. Patients are adults diagnosed with asthma, able to consent, with/without concomitant COPD. Before enrolment, 106 (72.1%) patients were treated with ICS/LABA and 41 (27.9%) with ICS/LABA/LAMA (both fixed or free combination).Patients at baseline had one or more exacerbations in the prior year (defined as moderate; 34.1%, severe; 32.6%, moderate and severe 33.3%) with a mean baseline moderate/severe exacerbation rate of 3.0/year. Mean rescue medication use at baseline was 11.2 puffs/week with 72.2% patients reporting an intake of rescue medication in the previous week. After twelve-months of treatment the mean change in moderate/severe exacerbation rate was -2.0/year (p<0.0001). Rescue medication use also significantly decreased (-4.6 puffs/week) compared to baseline (p=0.0037) along with a reduction in the proportion of patients reporting rescue medication use within the previous week (reduced to 63.6%).Conclusion Significant decreases in both moderate/severe exacerbation rate and rescue medication use were observed twelve-months after switching from an ICS/LABA or ICS/LABA/LAMA (both fixed or free combination) to treatment with SITT BDP/FF/G in adult patients with moderate-to-severe asthma.Reference Virchow JC, et al. Lancet. 2019;394(10210):1737–49.